HuGE Literature Finder
Records
1
-
6
Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Diagnostic pathology 2019 Jul 14 (1): 74. Huang Meiling, Yan Changjiao, Xiao Jingjing, Wang Ting, Ling R |
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World journal of gastroenterology 2016 Aug 22 (30): 6944-54. Lo Nigro Cristiana, Ricci Vincenzo, Vivenza Daniela, Granetto Cristina, Fabozzi Teresa, Miraglio Emanuela, Merlano Marco |
Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis. Molecular and clinical oncology 2016 Jun 4 (6): 1017-1024. Lin L I, Chen Lu-Lu, Wang You, Meng Xiang-Yu, Liang Chen, Zhou Fu-Xia |
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 Jan 26 (1): 13-21. Sorich M J, Wiese M D, Rowland A, Kichenadasse G, McKinnon R A, Karapetis C |
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Molecular cancer therapeutics 2014 Jul 13 (7): 1918-28. Xia Junfeng, Jia Peilin, Hutchinson Katherine E, Dahlman Kimberly B, Johnson Douglas, Sosman Jeffrey, Pao William, Zhao Zhongmi |
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden) 2014 Jul 53 (7): 852-64. Therkildsen Christina, Bergmann Troels K, Henrichsen-Schnack Tine, Ladelund Steen, Nilbert M |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 07, 2023
- Content source: